Association of High LAT1 Expression with Poor Prognosis and Recurrence in Colorectal Cancer Patients Treated with Oxaliplatin-Based Adjuvant Chemotherapy

被引:6
|
作者
Shibasaki, Yuta [1 ]
Yokobori, Takehiko [2 ]
Sohda, Makoto [1 ]
Shioi, Ikuma [1 ]
Ozawa, Naoya [1 ]
Komine, Chika [1 ]
Suga, Kunihiko [1 ]
Nakazawa, Nobuhiro [1 ]
Osone, Katsuya [1 ]
Shiraishi, Takuya [1 ]
Okada, Takuhisa [1 ]
Sano, Akihiko [1 ]
Sakai, Makoto [1 ]
Ogawa, Hiroomi [1 ]
Kaira, Kyoichi [3 ]
Shirabe, Ken [1 ]
Saeki, Hiroshi [1 ]
机构
[1] Gunma Univ, Grad Sch Med, Dept Gen Surg Sci, Maebashi 3718510, Japan
[2] Gunma Univ Initiat Adv Res GIAR, Div Integrated Oncol Res, Maebashi 3718511, Japan
[3] Saitama Univ Hosp, Comprehens Canc Ctr, Int Med Ctr, Dept Resp Med, Hidaka 3501298, Japan
基金
日本学术振兴会;
关键词
L-type amino acid transporter-1; cancer aggressiveness; prognostic marker; chemosensitivity marker; TRANSPORTER; FLUOROURACIL; LEUCOVORIN; LEVAMISOLE; RESISTANCE; THERAPY; ASCT2;
D O I
10.3390/ijms24032604
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The mammalian target of rapamycin (mTOR) is often activated in several cancers. We focused on two mTOR regulatory mechanisms: oxaliplatin-induced mTOR signaling and L-type amino acid transporter 1 (LAT1)-induced mTOR activation. High LAT1 expression in several cancers is associated with mTOR activation and resistance to chemotherapy. However, the significance of LAT1 has not yet been elucidated in colorectal cancer (CRC) patients treated with post-operative adjuvant chemotherapy. Immunohistochemistry was conducted to examine the significance of membrane LAT1 expression in 98 CRC patients who received adjuvant chemotherapy, including oxaliplatin. In vitro analysis was performed using CRC cell lines to determine the effects of LAT1 suppression on proliferation, oxaliplatin sensitivity, and mTOR signaling. LAT1 expression was associated with cancer aggressiveness and poor prognosis in 98 CRC patients treated with adjuvant chemotherapy. We found that positive LAT1 expression correlated with shorter survival in 43 patients treated with the capecitabine-plus-oxaliplatin (CAPOX) regimen. LAT1 suppression in CRC cells inhibited the proliferation potency and oxaliplatin-induced activation of mTOR signaling, and improved oxaliplatin sensitivity. LAT1 evaluation before adjuvant treatment may therefore be a sensitive marker for oxaliplatin-based regimens. Moreover, LAT1 may be a promising target for patients with refractory CRC.
引用
收藏
页数:13
相关论文
共 50 条
  • [41] Expression of DNA double-strand break repair proteins predicts the response and prognosis of colorectal cancer patients undergoing oxaliplatin-based chemotherapy
    Ihara, Keisuke
    Yamaguchi, Satoru
    Ueno, Nozomi
    Tani, Yukiko
    Shida, Yosuke
    Ogata, Hideo
    Domeki, Yasushi
    Okamoto, Kentaro
    Nakajima, Masanobu
    Sasaki, Kinro
    Tsuchioka, Takashi
    Mitomi, Hiroyuki
    Kato, Hiroyuki
    ONCOLOGY REPORTS, 2016, 35 (03) : 1349 - 1355
  • [42] Tumor Mutation Burden and Prognosis in Patients with Colorectal Cancer Treated with Adjuvant Fluoropyrimidine and Oxaliplatin
    Lee, Dae-Won
    Han, Sae-Won
    Bae, Jeong Mo
    Jang, Hoon
    Han, Hyojun
    Kim, Hyoki
    Bang, Duhee
    Jeong, Seung-Yong
    Park, Kyu Joo
    Kang, Gyeong Hoon
    Kim, Tae-You
    CLINICAL CANCER RESEARCH, 2019, 25 (20) : 6141 - 6147
  • [43] Treatment strategies to resectable metachronous colorectal liver metastases after adjuvant oxaliplatin-based chemotherapy for primary colorectal cancer
    Julio, Camille
    Benoist, Stephane
    Allard, Marc-Antoine
    Navarro, Francis
    Pessaux, Patrick
    Cunha, Antonio Sa
    Brouquet, Antoine
    JOURNAL OF SURGICAL ONCOLOGY, 2022, 126 (02) : 330 - 338
  • [44] Inflammatory cytokines and toxic effects of oxaliplatin-based chemotherapy in patients with colorectal cancer.
    Wang, X. S.
    Cleeland, C. S.
    Johnson, V. E.
    Reuben, J. M.
    Fogelman, D. R.
    Malekifar, M.
    Liao, K. E.
    Liu, P.
    Cohen, E. N.
    Gilmore, K. R.
    Eng, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [45] Impact of Oxaliplatin-based chemotherapy on the haemoglobin levels: A retrospective analysis in patients with colorectal cancer
    Queralt, Bernardo
    Juez, Ignacio
    Hernandez, Xavier
    Vinas, Gemma
    Rubio, Jordi
    Soler, Francesc
    Monleon, Antonio
    Colomer, Ramon
    ANNALS OF ONCOLOGY, 2004, 15 : 86 - 86
  • [46] Expressions of 10 genes as candidate predictors of recurrence in stage III colon cancer patients receiving adjuvant oxaliplatin-based chemotherapy
    Kumamoto, Kensuke
    Nakachi, Yutaka
    Mizuno, Yosuke
    Yokoyama, Masaru
    Ishibashi, Keiichiro
    Kosugi, Chihiro
    Koda, Keiji
    Kobayashi, Michiya
    Tanakaya, Kohji
    Matsunami, Toshio
    Eguchi, Hidetaka
    Okazaki, Yasushi
    Ishida, Hideyuki
    ONCOLOGY LETTERS, 2019, 18 (02) : 1388 - 1394
  • [47] Prognostic value of methylator phenotype in stage III colon cancer treated with oxaliplatin-based adjuvant chemotherapy
    Gallois, C.
    Taieb, J.
    Le Corre, D.
    Le Malicot, K.
    Tabernero, J.
    Mulot, C.
    Seitz, J-F.
    Aparicio, T.
    Folprecht, G.
    Lepage, C.
    Mini, E.
    Van Laethem, J-L.
    Emile, J. F.
    Laurent-Puig, P.
    ANNALS OF ONCOLOGY, 2017, 28
  • [48] XRCC1 and GSTP1 polymorphisms and prognosis of oxaliplatin-based chemotherapy in colorectal cancer: a meta-analysis
    Ye, Fanghui
    Liu, Zhenfang
    Tan, Aihua
    Liao, Ming
    Mo, Zengnan
    Yang, Xiaobo
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (03) : 733 - 740
  • [49] Oxaliplatin-based Chemotherapy in Patients Aged 75 Years or Older with Metastatic Colorectal Cancer
    Fukuchi, Minoru
    Ishibashi, Keiichiro
    Tajima, Yusuke
    Okada, Norimichi
    Yokoyama, Masaru
    Chika, Noriyasu
    Hatano, Satoshi
    Matsuzawa, Takeaki
    Kumamoto, Kensuke
    Kumagai, Youichi
    Baba, Hiroyuki
    Mochiki, Erito
    Ishida, Hideyuki
    ANTICANCER RESEARCH, 2013, 33 (10) : 4627 - 4630
  • [50] XRCC1 and GSTP1 polymorphisms and prognosis of oxaliplatin-based chemotherapy in colorectal cancer: a meta-analysis
    Fanghui Ye
    Zhenfang Liu
    Aihua Tan
    Ming Liao
    Zengnan Mo
    Xiaobo Yang
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 733 - 740